Comparative Pharmacology
Head-to-head clinical analysis: NEXIUM IV versus PREVACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXIUM IV versus PREVACID.
NEXIUM IV vs PREVACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. Esomeprazole is the S-isomer of omeprazole, which is concentrated in the acidic environment of parietal cells and converted to the active sulfenamide form that binds covalently with the proton pump, leading to irreversible inhibition.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
20-40 mg intravenously once daily; for GERD with erosive esophagitis: 20-40 mg once daily; for Zollinger-Ellison syndrome: 80 mg IV every 12 hours, adjust based on acid output.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults. In patients with hepatic impairment (Child-Pugh Class A, B, or C), half-life may be prolonged up to 2.9-8 hours.
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Renal (approx. 80% as inactive metabolites), fecal (approx. 20% as metabolites and parent drug). Less than 1% excreted unchanged in urine.
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor